1314874-80-0

Basic information

• Product Name: 8-Chloro-[1,2,4]triazolo[1,5-a]pyrazin-2-ylamine
• Synonyms: 8-Chloro-[1,2,4]triazolo[1,5-a]pyrazin-2-ylamine;8-chloro-[1,2,4]triazolo[1,5-a]pyrazin-2-amine
• CAS NO: 1314874-80-0
• Molecular Formula: C₅H₄ClN₅
• Molecular Weight: 169.57176
• Mol File: 1314874-80-0.mol

Chemical Properties

• Appearance: /
• Density: 1.95±0.1 g/cm3(Predicted)
• PKA: 1.40±0.30(Predicted)
• CAS DataBase Reference: 8-Chloro-[1,2,4]triazolo[1,5-a]pyrazin-2-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Chloro-[1,2,4]triazolo[1,5-a]pyrazin-2-ylamine(1314874-80-0)
• EPA Substance Registry System: 8-Chloro-[1,2,4]triazolo[1,5-a]pyrazin-2-ylamine(1314874-80-0)

Safety Data

• Hazardous Substances Data: 1314874-80-0(Hazardous Substances Data)

Upstream product

• 1314874-79-7 ethyl N-[(3-chloropyrazin-2-yl)carbamothioyl]carbamate 

Downstream Products

• 1314874-81-1 C₁₂H₈F₃N₅ 
• 1314786-27-0 N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-8-[3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrazin-2-amine 
• 1314873-89-6 3-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]amino]-5-[[3-(trifluoromethyl)phenyl]methyl]-1H-1,2,4-triazole-1-ethanamine 
• 1314873-76-1 C₂₅H₂₆F₃N₇O₂ 
• 1360612-76-5 C₁₅H₁₆N₆ 
• 1451386-37-0 N-(4-morpholinophenyl)-8-pyrido[2,3-b]pyrazin-7-yl-[1,2,4]triazolo[1,5-a]pyrazin-2-amine 
• 1451386-40-5 [8-(3-fluoro-4-morpholin-4-ylmethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl]-(4-morpholin-4-yl-phenyl)amine 
• 1360612-71-0 C₁₁H₉N₅O 

Relevant articles and documents

JAK INHIBITORS

Disclosed is a series of JAK inhibitors, which specifically relates to a compound shown in formula (I) or pharmaceutically acceptable salts thereof.

8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formuula (I) and (II), or a stereoisomer, tautomer, solvate, prodrug or salt thereof, and methods of use as Janus kinase inhibitors are described herein.

BRIDGED PIPERIDINE DERIVATIVES

The present invention relates to a compound of formula (I), wherein Het Ar is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, or lower alkoxy; R2 is lower alkyl substituted by halogen, -CH2-C3-6-cycloalkyl, substituted by one or two substituents, selected from lower alkyl substituted by halogen or halogen, or is lower alkenyl substituted by halogen; R3 is hydrogen, lower alkyl substituted by halogen, lower alkyl, halogen, C3-6-cycloalkyl or lower alkyl substituted by hydroxy; n is 1 or 2; for n = 2, R1 can be independent to each other; Y is CH or N; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

TRIAZOLOPYRAZINE DERIVATIVES

Compounds of the formula I in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment rheumatoid arthritis

NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS

The present invention is concerned with novel substituted triazole derivatives of Formula (I) wherein Het1, R1, R2, A1, A2, A3, A4, L1, and L2 have the mean

NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS

The present invention is concerned with novel substituted triazole derivatives of Formula (I) wherein Het1, R1, R2, A1, A2, A3, A4, L1, and L2 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma sec